Study on dose-effect relationship and safety of Modified Huangqi Chifeng Decoction with different doses of Astragalus in the treatment of IgA nephroproteinuria

Xiyuan Hospital, China Academy of Chinese Medical Sciences0 个研究点开始时间: 待定最近更新: 2023年2月20日

研究概览

暂无简介。

•1. The diagnosis was IgA nephropathy, and the pathologic reports of renal perforation were reported in all cases;
•2. No gender limitation, aged 18-70 years;
•3. Moderate proteinuria(24-hour urinary protein quantity is between 1.0-2.5g)accompanied or not accompanied by microscopic hematuria;
•4. CKD1-2 (GFR>=60ml/min/1.73m2);
•5. TCM syndrome differentiation accords with qi deficiency and blood stasis syndrome as well as wind pathogen and heat toxicity;
•6. Non-dialysis patients with infection, acidosis, electrolyte disturbance, hypertension and other aggravating factors are effectively controlled and the condition is stable. The BP is between 130-90/80-60mmHg. Potassium is in the normal range;
•7. Voluntarily accept this study and sign the informed consent form.

•1. Secondary factors leading to proteinuria, such as purpura nephritis, lupus nephritis;
•2. Patients who have been treated by glucocorticoid, immunosuppressant, tripterygium wilfordii preparation in three months are not included;
•3. Having mental illness, infectious disease or lactation, pregnancy or planned pregnancy during the study period;
•4. Patients complicated with serious diseases of the heart, brain, liver and hematopoietic system, or other serious diseases affecting their survival;
•5. Patients with unilateral or bilateral renal artery stenosis;
•6. Participants who are participating in other interventional clinical trials.

发起方